393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

• Vivek Khemka,
• Claire Friedman,
• Georgia Kollia,
• Paolo Ascierto,
• Mark O’Hara,
• Lee James,
• Bruce Fischer,
• Shilpa Demes,
• Martin Kozicki,
• Palanikumar Ravindran,
• Jacqueline Shoukry,
• Mona Yunan,
• Ashish Massey

Affiliations

Vivek Khemka

Aff1 grid.490596.7000000040424685XWestern Regional Medical Center Goodyear AZ USA

Claire Friedman

Aff1 grid.51462.340000000121719952Memorial Sloan Kettering Cancer Center 300 E 66th Street, BAIC 813 10065 New York NY USA

Georgia Kollia

Aff1 grid.419971.3Bristol-Myers Squibb Princeton NJ United States

Paolo Ascierto

6Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy

Mark O’Hara

4University of Pennsylvania, Philadelphia, PA, USA

Lee James

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Bruce Fischer

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Shilpa Demes

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Martin Kozicki

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Palanikumar Ravindran

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Jacqueline Shoukry

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Mona Yunan

7Bristol Myers Squibb, Lawrenceville, NJ, USA

Ashish Massey

7Bristol Myers Squibb, Lawrenceville, NJ, USA